Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

XellSmart Raises $27.6 Million for Low-Cost Stem Cell Therapies

publication date: Nov 8, 2022

Shanghai XellSmart Biomedical closed a $27.6 million in Series A1 financing to develop low-cost stem cell therapies for major unmet needs including Parkinson's disease. Founded in 2021, XellSmart has a 1,400-square-meter Shanghai R&D center and a 3,400-square-meter pilot production base in Suzhou under construction. Besides Parkingson’s, the company is developing stem cell therapies for retinopathy, brain trauma and cancer. The round was co-led by Qiming Venture, Lilly Asia Ventures, FIG and CSSD. Qiming and Lilly are previous investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital